QNTM

Quantum BioPharma Ltd. operates as a Canadian-based biotech acceleration and investment company focused on developing pharmaceutical and wellness products. Headquartered in Toronto, Ontario, the company concentrates on three primary business segments: developing innovative drug candidates targeting chronic pain and inflammation, commercializing bioactive compounds derived from cannabis and psychedelics, and investing in strategic healthcare opportunities. The company's portfolio includes Unbuzzd, a functional beverage designed to accelerate alcohol metabolism, and various preclinical-stage pharmaceutical programs investigating novel treatments for pain management without traditional opioid dependencies. Quantum BioPharma pursues a hybrid business model combining internal research and development with strategic acquisitions and partnerships to accelerate product commercialization. The company maintains research collaborations with academic institutions and contract research organizations to advance its pipeline. Recent developments include expanding its intellectual property portfolio around proprietary formulations and delivery mechanisms for cannabinoid and psychedelic-derived therapeutics. As a publicly traded entity on the Canadian Securities Exchange under ticker QNTM and the OTCQB market as QNTMF, the company positions itself within the emerging sector of alternative medicine and novel pharmaceutical development. Quantum BioPharma remains in growth stage, focusing on advancing candidates through preclinical and clinical development phases while exploring commercial opportunities for its consumer wellness products.